US trials of Cardima's ablation catheter begin:
This article was originally published in Clinica
Executive Summary
The first US patient has been successfully treated for atrial fibrillation with Cardima's Pathfinder ablation catheter. The 38-year old man, who had been suffering AF episodes almost every day over five years, was treated with the catheter and left hospital with a normal heart rhythm. The treatment was part of a feasibility trial of the device - a PMA trial is set to begin before the year end. In Europe, 12 patients have been treated so far for AF.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.